Regeneron Pharmaceuticals Inc
REGN759.180USD
+4.160+0.55%
收盤 02/03, 16:00（美東）報價延遲15分鐘
79.79B總市值
17.63本益比TTM
關於 Regeneron Pharmaceuticals Inc 公司
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc簡介
公司代碼REGN
公司名稱Regeneron Pharmaceuticals Inc
上市日期Apr 02, 1991
CEOSchleifer (Leonard S)
員工數量15106
證券類型Ordinary Share
年結日Apr 02
公司地址777 Old Saw Mill River Road
城市TARRYTOWN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編10591
電話17813705000
網址https://www.regeneron.com/
公司代碼REGN
上市日期Apr 02, 1991
CEOSchleifer (Leonard S)
Regeneron Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+14941.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.05K
+17578.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.18K
-2213.00%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+1080.00%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.17K
-743.00%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.06K
+155.00%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+2035.00%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.81K
+155.00%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+119.00%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.77K
+155.00%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+14941.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.05K
+17578.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.18K
-2213.00%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+1080.00%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.17K
-743.00%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.06K
+155.00%
收入明細
單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Sanofi
1.62B
43.07%
EYLEA
680.60M
18.13%
EYLEA HD
430.60M
11.47%
Bayer
344.80M
9.18%
Libtayo
219.10M
5.84%
其他
462.20M
12.31%
由於公司未披露，未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Sanofi
1.62B
43.07%
EYLEA
680.60M
18.13%
EYLEA HD
430.60M
11.47%
Bayer
344.80M
9.18%
Libtayo
219.10M
5.84%
其他
462.20M
12.31%
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.73%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
其他
74.18%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.73%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
其他
74.18%
股東類型
持股股東
佔比
Investment Advisor
45.29%
Investment Advisor/Hedge Fund
31.13%
Hedge Fund
5.04%
Pension Fund
2.77%
Research Firm
2.72%
Bank and Trust
2.20%
Individual Investor
2.07%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
其他
7.36%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
2674
93.48M
90.51%
-2.18M
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
9.00M
8.71%
-376.36K
-4.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.46M
5.29%
-204.21K
-3.60%
Sep 30, 2025
State Street Investment Management (US)
4.69M
4.54%
-140.78K
-2.91%
Sep 30, 2025
Dodge & Cox
4.55M
4.41%
+724.56K
+18.94%
Sep 30, 2025
JP Morgan Asset Management
2.95M
2.85%
+130.73K
+4.64%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.54M
2.46%
+70.84K
+2.87%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
2.32M
2.24%
+133.61K
+6.12%
Dec 31, 2025
Putnam Investment Management, L.L.C.
2.15M
2.08%
+117.43K
+5.78%
Sep 30, 2025
Capital World Investors
2.00M
1.93%
+32.35K
+1.65%
Sep 30, 2025
Loomis, Sayles & Company, L.P.
1.98M
1.92%
+38.38K
+1.98%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比6.6%
Invesco Nasdaq Biotechnology ETF
佔比6.55%
Amplify Weight Loss Drug & Treatment ETF
佔比6.4%
iShares Biotechnology ETF
佔比5.9%
Simplify Health Care ETF
佔比5.54%
VanEck Biotech ETF
佔比5.51%
Invesco Biotechnology & Genome ETF
佔比5.4%
iShares Genomics Immunology and Healthcare ETF
佔比4.97%
First Trust NASDAQ Pharmaceuticals ETF
佔比4.36%
First Trust NYSE Arca Biotechnology Index Fund
佔比3.88%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Jan 30, 2026
REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026
Feb 20, 2026
Mar 05, 2026
Feb 20, 2026
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
